Board revokes patent on Roche hepatitis drug

MUMBAI Fri Nov 2, 2012 7:23pm IST

A pharmacist gives medicine to a patient inside a government hospital in Kolkata July 3, 2012. REUTERS/Rupak De Chowdhuri/Files

A pharmacist gives medicine to a patient inside a government hospital in Kolkata July 3, 2012.

Credit: Reuters/Rupak De Chowdhuri/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - India's patents appeal board has revoked a patent granted to Roche's hepatitis C drug Pegasys, citing a lack of evidence the drug is superior tp existing treatments, and its high price.

The decision is another setback for large pharmaceutical companies in India, which earlier this year granted the first ever compulsory licence to domestic drugmaker Natco (NATP.NS) to sell cheap copies of Bayer AG's(BAYGn.DE) cancer drug Nexavar.

Global drugmakers see India's $12 billion drug market as a huge opportunity, but they are wary of protection for intellectual property in a country where generic medicines account for more than 90 percent of sales.

Sankalp Rehabilitation Trust, an advocacy group for cheaper medicines, challenged the Pegasys patent with the Intellectual Property Appellate Board, saying the drug was costly and gave the Swiss company a monopoly in the market for the drug.

The market price of Pegasys is 436,000 rupees for 48 weeks of treatment, and it is also available at a discounted price of 314,496 rupees, Sankalp said in a statement.

Pegasys is to be taken in combination with another drug, ribavirin, which costs 47,160 rupees for the same period, Sankalp added.

The appeals board on Friday termed Sankalp's plea "valid."

Roche, which can appeal the decision to India's Supreme Court, could not immediately be reached for comment.

(Reporting by Kaustubh Kulkarni; Editing by Tony Munroe and Helen Massy-Beresford)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Consumer Confidence Index

REUTERS SHOWCASE

Deal Talk

Deal Talk

Exclusive - Lupin, U.S. firms weigh bids for GSK's mature drugs: sources  Full Article 

Classifying Banks

Classifying Banks

RBI to start announcing too-big-to-fail banks in Aug 2015  Full Article 

Corruption Probe

Corruption Probe

India to probe corruption in healthcare after TV sting.  Full Article 

Food Scandal

Food Scandal

Starbucks, Burger King dragged in as China food scandal spreads.  Full Article 

Bigger iPhones

Bigger iPhones

Apple asks suppliers to produce up to 80 mln large-screen iPhones - WSJ.  Full Article 

Bali Trade Deal

Bali Trade Deal

India keeps world guessing in countdown to landmark trade pact deadline.  Full Article 

Bangalore Sex Abuse

Bangalore Sex Abuse

Modi's BJP puts political twist on local sex abuse case   Full Article 

Yahoo to buy Flurry

Yahoo to buy Flurry

Yahoo to buy analytics startup Flurry to bolster mobile ad business.  Full Article 

Wholesale Biz

Wholesale Biz

Wal-Mart adds $102.9 million in Indian wholesale business in June.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage